) at the onset of reperfusion markedly reduced infarct volume from 54.32% to 13.03%, significantly improved neurological function, and enhanced locomotor recovery in a dose-dependent manner. Mechanistically, the nanozyme exerted dual therapeutic effects through both direct ROS scavenging and activation of the Nrf2/xCT/GPX4 antioxidant signaling pathway, thereby maintaining glutathione homeostasis and cellular redox balance. Furthermore, treatment restored the expression of brain-derived neurotrophic factor (BDNF) and postsynaptic density protein 95 (PSD95), increased the levels of SIRT1 and PGC-1α, and reduced the expression of GFAP and iNOS, indicating the preservation of neuronal plasticity and mitochondrial homeostasis, together with the attenuation of reactive gliosis. Collectively, these findings highlight Meso-Cu-PBMc as a promising therapeutic platform for the treatment of ischemia-reperfusion injury and other oxidative stress-associated neurological disorders.